What is the pathophysiology of acute pancreatitis and how should it be managed?

Acute Pancreatitis: Pathophysiology and Management

Pathophysiology

Acute pancreatitis results from premature intrapancreatic activation of digestive enzymes, triggering autodigestion of pancreatic tissue and initiating a local inflammatory cascade that can progress to systemic inflammatory response syndrome (SIRS) and multiorgan failure. 1

Local Inflammatory Process

• Interstitial edema is the hallmark pathological finding in mild acute pancreatitis, representing the primary histologic change in limited disease 1
• Pancreatic necrosis develops in severe cases, appearing as diffuse or focal areas of non-viable pancreatic parenchyma accompanied by peripancreatic fat necrosis 1
• Infected necrosis occurs in 20-40% of severe cases and carries a mortality rate of 35.2% when combined with organ failure 1

Systemic Inflammatory Mediators

• Injured pancreatic tissue and activated immune cells release pro-inflammatory cytokines including IL-1β, IL-6, IL-8, TNF-α, and platelet-activating factor into the systemic circulation 1
• Secretory phospholipase A₂ type II (sPLA₂-II) peaks within 48 hours of disease onset and correlates directly with the development of multiple-organ complications 1
• Local concentrations of IL-1β and IL-10 in peripancreatic fluid collections are markedly higher than systemic levels, indicating that excessive local cytokine synthesis drives systemic lymphocyte activation 1
• Persistent organ failure lasting more than 48 hours is the strongest predictor of mortality in acute pancreatitis 1

---

Diagnosis

Diagnosis requires meeting at least two of three criteria: 1

1. Epigastric abdominal pain consistent with acute pancreatitis (radiating to the back, worse with eating)
2. Serum lipase or amylase >3 times the upper limit of normal
3. Imaging findings of pancreatic inflammation on cross-sectional imaging

Essential Diagnostic Workup

• Right upper quadrant ultrasound to identify gallstones (the leading cause, accounting for 45-60% of cases) 2, 1
• Serum triglycerides (hypertriglyceridemia accounts for 4-10% of cases and carries worse prognosis) 2
• Full blood count, renal and liver function tests, glucose, calcium 3
• Chest imaging 3
• Dynamic CT scan if diagnostic uncertainty exists or to detect complications when C-reactive protein exceeds 150 mg/L 3

---

Severity Classification

The 2012 revised Atlanta classification categorizes severity as mild, moderate, or severe based on organ failure duration and local complications: 1

• Mild: Interstitial edema only, minimal organ dysfunction, typically uneventful recovery 1
• Moderately severe: Transient organ failure (<48 hours) and/or local complications 1
• Severe: Persistent organ failure (>48 hours) and/or local complications such as necrosis, pseudocyst, or abscess; overall mortality approaches 15%, rising to 35.2% when infected necrosis coexists with organ failure 1

---

Initial Management

Fluid Resuscitation

• Goal-directed fluid therapy is recommended, though evidence quality is low 4
• No preference exists between normal saline or Ringer's lactate 4
• Avoid hydroxyethyl starch fluids as they increase multiple organ failure risk (OR 3.86) 4

Pain Management

• Adequate analgesia is a priority in initial management 1, 3

Nutritional Support

• Early oral feeding within 24 hours is strongly recommended rather than keeping patients NPO 1, 4
• Enteral nutrition is preferred over parenteral nutrition if oral feeding is not tolerated 4
• Patients should not be kept NPO beyond 24 hours as early feeding improves outcomes 4

Antibiotic Use

• Antibiotics are indicated only for radiologically confirmed infected necrosis or systemic infection 1
• Antibiotic prophylaxis for sterile necrosis remains controversial; if used, it should be restricted to patients with substantial pancreatic necrosis (≥30% of gland) and continued for no more than 14 days 5

---

Management of Necrosis

Sterile Necrosis

• Sterile necrosis does not usually require therapy 5
• Surgery has no role in severe pancreatitis with sterile necrosis 5

Infected Necrosis

• Suspect infected necrosis in patients with preexisting sterile pancreatic necrosis who develop persistent or worsening symptoms or signs of infection, typically after 7-10 days of illness 5
• CT-guided fine-needle aspiration should be performed with culture and Gram stain to document infection 5
• Antibiotic therapy should be tailored based on fine-needle aspiration results 5
• Patients with infected necrosis should be managed in centers with specialist units with appropriate endoscopic, radiologic, and surgical expertise 5
• Management depends on patient acuity, response to antibiotics, consistency of necrotic material, and local expertise 5
• Minimally invasive step-up approaches have replaced maximally invasive necrosectomy as the preferred intervention strategy 6

---

Etiology-Specific Management

Gallstone Pancreatitis (45-60% of cases)

• Urgent ERCP with sphincterotomy and stone extraction is indicated for gallstone pancreatitis with cholangitis or jaundice 1
• Definitive surgical management (cholecystectomy) should be performed during the same hospital admission if possible for mild gallstone pancreatitis, otherwise no later than 2-4 weeks after discharge 5, 1
• Same-admission cholecystectomy reduces early readmission by 85% 4
• Endoscopic sphincterotomy alone provides adequate long-term therapy only in patients without a gallbladder in situ 5

Alcoholic Pancreatitis (20-25% of cases)

• Patients should be referred to alcohol counseling services and smoking cessation services 5, 2

Hypertriglyceridemia-Associated Pancreatitis (4-10% of cases)

• Initial management includes nil by mouth for 24-48 hours, aggressive fluid resuscitation, analgesia, and etiology-specific interventions such as in-hospital pharmacological treatment with insulin and/or heparin 2
• Plasmapheresis for severe cases 2
• Long-term prevention includes low-fat diet, weight loss, fibrate as first-line therapy, and addition of statin if concurrent hypercholesterolemia is present 2
• Tight regulation of triglyceride levels after initial presentation significantly reduces recurrence risk 2

Drug-Induced Pancreatitis

• Azathioprine and 6-mercaptopurine cause pancreatitis in approximately 4% of treated IBD patients, typically within the first 3-4 weeks of treatment 2
• Mesalazine (5-ASA compounds) also carries pancreatitis risk, though much lower than thiopurines 2

---

Management of Fluid Collections and Pseudocysts

• Acute fluid collections around the pancreas require no therapy in the absence of infection or obstruction of a surrounding hollow viscus 5
• Clinicians should not mistake collections of walled-off necrosis as simple pseudocysts; the internal consistency is best determined by EUS or magnetic resonance imaging 5
• Symptomatic, mature, encapsulated pseudocysts should be managed based on local expertise with endoscopic, percutaneous, or surgical techniques 5

---

Prevention of Post-ERCP Pancreatitis

• ERCP should be avoided if alternative diagnostic tests (CT, magnetic resonance cholangiopancreatography, or EUS) can provide similar diagnostic information 5
• ERCP should be performed by endoscopists with appropriate training and experience 5
• Endoscopists performing ERCP should have the technical skill to place pancreatic duct stents in high-risk situations 5
• Pregnancy increases post-ERCP pancreatitis risk to 12% versus 5% in non-pregnant patients 4

---

Critical Care Considerations

• Severe acute pancreatitis requires management in HDU/ITU setting with full systems support, including fluid resuscitation, pain control, nutritional support 1
• Approximately one-third of deaths occur early from multiple organ failure, and most deaths after the first week result from infected necrosis 1

---

Common Pitfalls to Avoid

• Do not use hydroxyethyl starch fluids as they increase multiple organ failure risk 4
• Do not keep patients NPO beyond 24 hours as early feeding improves outcomes 4
• Do not delay cholecystectomy unnecessarily in gallstone pancreatitis as conservative management leads to 60% recurrence of biliary symptoms 4
• Do not mistake walled-off necrosis for simple pseudocysts; use EUS or MRI to determine internal consistency 5
• Do not use tocilizumab for ARDS in severe acute pancreatitis due to lack of supporting evidence, heightened infection risk, and mechanistic differences from COVID-19-related cytokine storm 1